Vanadium Compounds Patented for Cancer Treatment

The United States Patent and Trademark Office (USPTO) has issued patent US12582672B2, granting The Broad Institute, Inc. exclusive rights to specific vanadium compositions and methods for treating cancers. The patent focuses on targeting cancers that exhibit elevated expression of SLC26A2, such as certain ovarian, endometrial, brain, bone, and lung cancers, as well as melanoma. The disclosed therapeutic agent is bis(maltolato)oxovanadium(IV) (BMOV) and related vanadium-containing compounds, which are claimed to kill SLC26A2 expressing cancer cells in a dependent manner.

This patent grant represents a new intellectual property asset in the field of cancer therapeutics. While it does not impose direct compliance obligations on other entities, it signifies potential future market exclusivity for The Broad Institute in this specific therapeutic area. Companies involved in oncology drug development, particularly those working with vanadium compounds or targeting SLC26A2, should be aware of this patent to avoid potential infringement and to inform their own research and development strategies. No specific compliance deadlines or penalties are associated with this patent grant itself, but future commercialization by the assignee could lead to licensing opportunities or competitive challenges.